Clinical Trials Directory

Trials / Completed

CompletedNCT03656055

Analysis of Neurodegenerative Process Within Visual Ways In Multiple Sclerosis

Study of the Link Between Retinal Atrophy and Demyelinating Inflammatory Processes on Visual Pathways in Relapsing Multiple Sclerosis in Magnetic Resonance Imaging and Optical Coherence Tomography

Status
Completed
Phase
Study type
Observational
Enrollment
108 (actual)
Sponsor
University Hospital, Lille · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This study will interest in the pathophysiology of silent retinal axonal loss in multiple sclerosis. Recent studies have suggested that silent retinal axonal loss (no past history of optic neuritis \[ON\]) may be due to inflammatory lesions within the optic radiations and a transsynaptic degenerative process. The objective is to measure the exact role of silent optic nerve lesion in the occurrence of silent retinal axonal loss by performing OCT, brain and optic nerve MRI in a cohort of patients without recent disease activity.

Detailed description

This study will interest in the neurodegenerative process reported in multiple sclerosis within the visual ways. Symptomatic and asymptomatic retinal axonal loss in multiple sclerosis (MS) have largely been described. Many recent optical coherence tomography (OCT) studies have suggested that subclinical retinal axonal loss (no past history of optic neuritis \[ON\]) observed in MS mainly due to inflammatory and demyelinating lesions within the optic radiations and a retrograde transsynaptic degenerative process. None of these studies clearly tried to investigate the role of asymptomatic optic nerve lesion(s) in subclinical retinal axonal loss occurence. The main objective of the study is to measure the exact role of silent optic nerve lesion in the occurrence of silent retinal axonal loss by performing OCT, brain and optic nerve MRI. The study will focus on a cohort of patients without recent disease activity in order to exclude or minimize the risk of recent and old lesion occurence on the visual ways, which could be a bias in our analysis.

Conditions

Timeline

Start date
2017-04-21
Primary completion
2018-01-03
Completion
2019-01-03
First posted
2018-09-04
Last updated
2022-09-21

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03656055. Inclusion in this directory is not an endorsement.